CV Lattes
Secretaria da Saúde (São Paulo - Estado). Instituto Butantan (Institutional affiliation from the last research proposal) Birthplace: Brazil
Dr Irina holds a degree in Biology and Chemistry from the Federal University of Tomsk (1978), a master's degree in Biology and Chemistry from the Federal University of Tomsk (1981), and a Ph.D. in Cytogenetics from the Institute of Cytology and Genetics (1989). Recognition by the University of São Paulo for the Doctor in Sciences - Biology (Genetics) title in 2004. She obtained a Licentiate in Biological Sciences from the Russian Academy of Sciences in 1994. She is currently the director of the Genetics Laboratory at the Butantan Institute and a Level VI researcher at the Butantan Institute. She has extensive experience, leadership, and training in Biology. Her current focus is translational medicine using immature stem cells from human dental pulp in neurodegenerative and hematopoietic diseases. It has filed over fifty patents (20 of which have already been assigned) in the large-scale production of dental pulp stem cells and their use for treating neurodegenerative diseases. The technology was licensed by the Brazilian company Cellavita Pesquisas Cientificas Ltd, which carried out two clinical studies regulated by ANVISA, which showed the safety and effectiveness of the treatment for patients with Huntington's disease (HD). Another phase 1/2 clinical study was developed with COVID-19 patients. Currently, the company, in partnership with Instituto Butantan, is moving to carry out the phase III study in HD and to register the product. She has published more than 120 scientific articles and 20 book chapters. She has also served as a keynote speaker at national and international scientific events and has received numerous awards. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Successful drug development requires a disease target that plays a vital role in the causation and/or progression of the disease phenotype and that can be modulated with a drug molecule. In other words, therapeutically relevant targets are both “disease-modifying” and “druggable”. It has been estimated that around 10% of the entire human genome is involved in disease onset or progression,…
Recent findings on heterogeneity, flexibility and plasticity of stem cells are challenging the traditional concept of stem cells as pre-programmed entities. The concept of self-organizing systems offers an alternative, more elegant and comprehensive explanation for the experimental data. In recent decades, biological studies of stem cells have evolved a broad spectrum of phenomena, rangin…
The aim of the Interinstitutional Center for Applied Toxinology is to establish a world-class center for research into natural toxins. The Center will develop the study of toxins with the aim to investigate their potential therapeutic use, to foster contacts between science and industry and to raise the level of scientific human resources. The Institute Butantan with its history and tradi…
Osteoclasts acts in bones maintenance, repair and remodeling. Bone diseases such as Osteoporosis and Rheumatoid Arthritis have increased osteoclastogenesis, a devastating effect for bone loss. Therefore, there is a critical importance in the study of specific proteins or signaling pathways in the process of osteoclast differentiation. This process will be studied in a model of Peripheral …
Crotamine is a basic polypeptide found in the venom of Crotalus durissus terrificus. Crotamine is of great biotechnological interest since it is classified as a cell penetrating peptide (CPP), this feature is directed mainly to cells in proliferation, what proposes that tumour cells could be a target of it. Recently it was addressed in the literature, a new activity of crotamine in the st…
Aplastic anemia is a disease characterized by a partial or complete bone marrow failure, through a pluripotent Stem Cell Hematopoietic (HSC) assault, leading to decline and even absence of bone marrow. The treatment is typically given by HSC transplantation and administration of immunosuppressive drugs, but these processes are restricted since the necessity of cell compatibility to the ef…
(Only some records are available in English at this moment)
| 6 / 3 | Completed research grants |
| 14 / 9 | Completed scholarships in Brazil |
| 20 / 12 | All research grants and scholarships |
| Associated processes | |